Maze Therapeutics
secret to health
view our programs pipeline

latest press releases

November 04, 2023
Maze Therapeutics Highlights New Preclinical Data Supporting Advancement of APOL1 Inhibitor Candidate Toward Clinical Evaluation for APOL1 Kidney Disease
October 13, 2023
Maze Therapeutics to Present New Data for APOL1 Kidney Disease in Proprietary Chronic Preclinical Model Demonstrating Reversal of Albuminuria
October 11, 2023
Maze Therapeutics Announces Publication of Research Demonstrating Newly Identified Variant for APOL1 Kidney Disease is Associated with Reduced Risk of APOL1 Kidney Disease

latest media coverage

September 26, 2023
The Endpoints 11: The biotech startups making the biggest bets with the most exciting science in 2023
May 1, 2023
Biotech Startup Maze Therapeutics Strikes $750 Million Deal With Sanofi
May 1, 2023
Sanofi bets $750M to enter glycogen-lined Maze deal with lead asset waiting in the middle
May 1, 2023
Biotech Startup Maze Therapeutics Strikes $750 Million Deal With Sanofi
May 1, 2023
Sanofi strikes a $150M deal for Maze’s Pompe disease drug
May 1, 2023
Sanofi’s next chapter in Pompe: $150M for Maze pact as the biotech gears up in CKD
May 1, 2023
Sanofi stock rises on licensing deal with Maze for potential Pompe disease drug
May 1, 2023
Early clinical data drove Sanofi’s decision to license Maze’s oral Pompe therapy
May 1, 2023
Sanofi pumps up its Pompe portfolio with Maze deal
May 1, 2023
Sanofi Finds Way to Maze Therapeutics to Get Its Next Pompe Disease Drug
December 16, 2022
Updated: Maze reveals positive first look at PhI Pompe disease candidate
June 29, 2022
LifeSci 2nd Annual Genetic Medicines Symposium 2022
March 23, 2021
Exclusive: Maze unveils their $191M pipeline, taking on Vertex and two long-sought conditions
December 7, 2020
Maze Allies With BridgeBio and Alloy to Create 2 Biotechs
December 7, 2020
Endpoints News: Maze Therapeutics Spins Out Two New Companies with Alloy and BridgeBio
January 6, 2020
Top Life Sciences Startups to Watch in 2020
February 28, 2019
Forbes: Third Rock And ARCH-Backed Genetics Startup Launches With Nearly $200 Million
February 28, 2019
Xconomy: With $191M Haul, Maze Therapeutics Takes Aim at Genetic Diseases
February 28, 2019
MIT Technology Review: The secret to a new drug could be hiding in your genes

      want to get a hold of a representative?

      Jillian Connell
      Maze Therapeutics
      jconnell@mazetx.com

      media inquires

      Katie Engleman
      1AB
      katie@1abmedia.com

      Contact Us